Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Idifarma Strengthens Palobiofarma Relationship With Seventh Project

By Idifarma | November 1, 2018

Spanish contract development and manufacturing organization (CDMO) Idifarma has begun its seventh project with Spanish biotechnology company, Palobiofarma.

Under the terms of the agreement, Idifarma will handle the full pharmaceutical development of Palobiofarma’s new development candidate, the compound  PBF-2897. This will include drug formulation, development of analytical methods, and GMP manufacturing for clinical trials from its EU GMP facility in Pamplona, Spain.

PBF-2897 represents a novel co-crystal form of PBF-680, which is a potent, non-BBB permeable, adenosine A1 receptor antagonist as a first in class oral treatment of respiratory diseases as asthma and COPD currently in Phase II clinical trials. The PBF-2897 project is scheduled for completion in 2019. 

“Palobiofarma and Idifarma have had a strong relationship for most of the decade, successfully working together on six projects since 2012, and this latest project extends and strengthens that relationship,” said Luis Oquiñena, general manager and co-founder of Idifarma. 

Palobiofarma is a Spanish biotechnology company founded in 2006 and focused on the discovery and development of new medicines based on the modulation of the adenosine pathways.

The company signed a licensing deal with Novartis in 2015 for the compound PBF-509, a first in class lung cancer therapy which pharmaceutical development has been carried out by the Idifarma team.

Idifarma recently invested in both capsule filling and spray drying capabilities to strengthen its position as a specialized contract partner for the development and manufacturing of oral solid dosage forms, including high potency compounds and niche pharmaceuticals requiring small commercial and clinical batches.

(Source: Idifarma)

Related Articles Read More >

Pfizer logo
Pfizer seeks to comply with voluntary Net-Zero Standard by 2040
Cambridge Pharma launches with UK plant in Cambridge Research Park
Entegris logo
Entegris opens Life Sciences Technology Center in Massachusetts
sustainability
How pharma can optimize for right-the-first-time drug manufacturing and sustainability

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards